（文章来源：证券日报） 证券日报网讯 11月20日晚间，皓元医药发布公告称，公司于2024年11月28日向不特定对象发行的可转 换公司债券（简称"皓元转债"）将于2025年11月28日开始支付自2024年11月28日至2025年11月27日期间 的利息。 ...

Core Points - Haoyuan Pharmaceutical announced that its stock has triggered the conditional redemption clause for its convertible bonds due to the closing price exceeding 130% of the conversion price for 15 out of 30 trading days [2] - The company decided not to exercise the early redemption rights for the "Haoyuan Convertible Bonds" during the upcoming six-month period [2] - Future assessments for potential redemption will be conducted after May 20, 2026, if the redemption clause is triggered again [2]

Core Viewpoint - The article discusses various convertible bonds, highlighting their redemption status, trading prices, and key dates for conversion and redemption [1][4][6]. Group 1: Convertible Bonds Status - Guocheng Convertible Bond (127019) is subject to strong redemption on November 20, 2025 [1]. - Southeast Convertible Bond (127103) will not undergo adjustment [1]. - Huicheng Convertible Bond (118049) and Haoyuan Convertible Bond (118051) are not subject to strong redemption [1]. - Yinbang Convertible Bond (123252) will not be adjusted [1]. - Zhongjin Convertible Bond (127020) has its last trading day on November 20, 2025 [1]. Group 2: Pricing and Trading Information - Luokai Convertible Bond (113689) current price is 156.168, with a strong redemption price of 100.038, and a last trading day on November 17, 2025 [4]. - Chengfeng Convertible Bond (113628) current price is 153.032, with a last trading day on November 17, 2025 [4]. - Zhongjin Convertible Bond (127020) current price is 124.350, with a strong redemption price of 100.700, and a last trading day on November 20, 2025 [4]. - Hengbang Convertible Bond (127086) current price is 118.195, with a strong redemption price of 100.280, and a last trading day on November 24, 2025 [4]. - Qibin Convertible Bond (113047) current price is 113.481, with a strong redemption price of 101.174, and a last trading day on November 27, 2025 [4]. Group 3: Additional Convertible Bonds Information - Fenghuo Convertible Bond (110062) current price is 106.676, with a redemption price of 106.000, and a last trading day on November 26, 2025 [6]. - Ying19 Convertible Bond (110063) current price is 113.327, with a redemption price of 111.000, and a last trading day on December 12, 2025 [6]. - Hongda Convertible Bond (404003) current price is 54.781, with a redemption price of 118.000, and a last trading day on December 15, 2025 [6]. - Jianguo Convertible Bond (110064) current price is 113.369, with a redemption price of 113.000, and a last trading day on December 16, 2025 [6].

Summary of Key Points Core Viewpoint - The article discusses recent corporate actions and developments in the convertible bond market, highlighting shareholding changes, partnerships, and upcoming bond listings and trading dates. Group 1: Corporate Actions - Jia Mei Packaging's shareholders plan to reduce their holdings by no more than 1.16% of the company's shares [1] - Hailianxun's request for acquisition rights has ended, with trading resuming on November 19 [1] - Jiemai Technology's subsidiary, Rouzhen Technology, signed a cooperation development framework agreement with Ningde New Energy [1] Group 2: Convertible Bonds - The article lists various convertible bonds with their current prices, redemption prices, last trading dates, conversion values, remaining scales, and their proportion to the underlying stocks [1][4][6] - Notable upcoming bond listings include: - Qizhong Convertible Bond on November 21 - Maolai Convertible Bond on November 21 for subscription - Zhuomei Convertible Bond on November 24 - Other bonds with specific trading and conversion dates detailed [1][4][6] Group 3: Market Data - The article provides detailed tables of convertible bonds, including their current prices, conversion values, and market capitalization ratios, indicating the financial health and market positioning of these bonds [1][4][6]

Core Points - The company Shanghai Haoyuan Pharmaceutical Co., Ltd. has announced that its convertible bond "Haoyuan Convertible Bond" is expected to meet the redemption conditions due to the stock price performance [2][15]. Summary by Sections Convertible Bond Issuance Overview - The company issued 8.2235 million convertible bonds with a face value of RMB 100 each, totaling RMB 82.235 million, with a term of 6 years [2]. - The bonds were approved by the China Securities Regulatory Commission and listed on the Shanghai Stock Exchange on December 19, 2024 [3]. Convertible Bond Conversion Period - The bonds can be converted into shares from June 4, 2025, to November 27, 2030, with an initial conversion price of RMB 40.73 per share [4]. Conversion Price Adjustments - The conversion price has been adjusted multiple times due to various corporate actions, with the latest adjustment setting the conversion price at RMB 40.47 per share as of October 22, 2025 [8][9]. Redemption Terms and Conditions - The company has outlined redemption terms, including a mandatory redemption at 113% of the face value upon maturity and conditional redemption if certain stock price thresholds are met [10][11]. - The conditional redemption can occur if the stock price remains above 130% of the conversion price for a specified number of trading days [11][15]. Current Stock Performance - As of the announcement date, the company's stock has closed above the conversion price threshold for 10 trading days, indicating a potential trigger for the conditional redemption clause [2][15].

Core Viewpoint - Haoyuan Pharmaceutical announced that its stock price has been above 130% of the current conversion price of its convertible bonds for 10 trading days, which may trigger conditional redemption terms if the stock price remains above this threshold for an additional 5 trading days within the next 20 trading days [1] Summary by Relevant Sections - Stock Performance - The company's stock price has not fallen below 52.61 yuan per share, which is 130% of the current conversion price of the "Haoyuan Convertible Bonds" [1] - Redemption Conditions - If the stock price remains above the conversion price for 5 out of the next 20 trading days, the company has the right to redeem all or part of the unconverted "Haoyuan Convertible Bonds" at face value plus accrued interest [1]

Core Viewpoint - The China Convertible Bond Index experienced a decline of 0.52% on October 30, closing at 486.1 points, indicating a downward trend in the convertible bond market [1] Summary by Category Market Performance - The top decliners in the convertible bond market included Shuiyang Convertible Bond, Anke Convertible Bond, Haoyuan Convertible Bond, Jincheng Convertible Bond, and Haomei Convertible Bond, with declines of 6.53%, 3.97%, 3.9%, 3.72%, and 3.28% respectively [1] - Conversely, the top gainers were Dazhong Convertible Bond, Bojun Convertible Bond, Hangyang Convertible Bond, Chunyuan Convertible Bond, and Rundata Convertible Bond, which saw increases of 14.2%, 7.42%, 5.87%, 4.99%, and 3.86% respectively [1]

Core Points - The company announced an adjustment in the total cash dividend amount for the first half of 2025, maintaining a cash dividend of 0.80 yuan per 10 shares (including tax) [2] - The total cash dividend amount was adjusted from 16,967,901.20 yuan (including tax) to 16,967,993.52 yuan (including tax) [2] - The adjustment is due to the increase in the number of shares participating in profit distribution as a result of the company's publicly issued "Haoyuan Convertible Bonds" being in the conversion period [2]

Core Points - The announcement details the conversion results of the convertible bonds issued by Shanghai Haoyuan Pharmaceutical Co., Ltd. and the changes in share capital as of September 30, 2025 [1][2] Group 1: Convertible Bond Conversion Status - As of September 30, 2025, a total of RMB 464,000 of "Haoyuan Convertible Bonds" has been converted into company shares, resulting in 11,412 shares, which accounts for 0.0054% of the total shares before conversion [2][6] - The amount of "Haoyuan Convertible Bonds" that has not been converted as of September 30, 2025, is RMB 821,886,000, representing 99.94% of the total issuance [2][6] - During the period from July 1, 2025, to September 30, 2025, RMB 414,000 of "Haoyuan Convertible Bonds" was converted into shares, totaling 10,190 shares, which is 0.0048% of the total shares before conversion [2][6] Group 2: Convertible Bond Issuance Overview - The company issued 8,223,500 convertible bonds on November 28, 2024, with a total value of RMB 82,235,000 and a maturity of 6 years [3] - The bonds were listed for trading on December 19, 2024, under the name "Haoyuan Convertible Bonds" with the code "118051" [3] - The initial conversion price was set at RMB 40.73 per share, with adjustments made due to various corporate actions [3][4][5] Group 3: Share Capital Changes - The total share capital of the company was reduced by 47,725 shares on July 4, 2025, due to the cancellation of shares related to performance commitments [7] - The company completed the registration of 648,570 shares from the 2022 restricted stock incentive plan on July 8, 2025, which were then listed for trading [8] - Additional shares from the 2023 restricted stock incentive plan were also registered and listed for trading in subsequent months [8]

Core Viewpoint - The company announces the suspension of the conversion of its convertible bonds "Hao Yuan Convertible Bonds" during the implementation of the 2025 semi-annual profit distribution plan, which includes a cash dividend of 0.80 yuan per 10 shares [2][3]. Summary by Sections 1. Securities Suspension and Resumption - The "Hao Yuan Convertible Bonds" will stop conversion from October 13, 2025, until the equity registration date for the profit distribution [2][4]. - The bonds will resume conversion on the first trading day after the equity registration date [4]. 2. Profit Distribution Plan - The company will distribute a cash dividend of 0.80 yuan (including tax) for every 10 shares based on the total share capital registered on the equity registration date [3]. - The distribution plan does not include bonus shares or capital reserve conversion into share capital [3]. - The company will adjust the conversion price of the "Hao Yuan Convertible Bonds" according to the terms outlined in the prospectus after the profit distribution [3]. 3. Additional Information - Detailed information regarding the "Hao Yuan Convertible Bonds" can be found in the prospectus disclosed on November 26, 2024 [5].